MannKind (MNKD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
20 May, 2026Opening remarks and agenda
Meeting called to order with introductions of board members and corporate officers present, including remote participation.
Notice of meeting mailed to all stockholders; Inspector of Elections appointed and sworn in.
Quorum established with 233,461,993 shares represented, authorizing business transactions.
Board and executive committee updates
Nine directors nominated and elected to serve until the next annual meeting.
Board and executive team introduced, with CEO remarks scheduled after formal business.
Shareholder proposals
Three proposals presented: election of directors, advisory approval of executive compensation, and ratification of Deloitte & Touche as auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MannKind
- Q1 2026 revenue up 15% to $90.2M, but higher expenses led to a $16.6M net loss.MNKD
Q1 20267 May 2026 - Record 2025 revenue and strong Q4 growth set up major FDA catalysts for 2026.MNKD
Q4 20258 Apr 2026 - Key votes include board elections, executive pay approval, and auditor ratification for 2026.MNKD
Proxy filing7 Apr 2026 - Annual meeting to vote on directors, executive pay, and auditor, with focus on governance and performance.MNKD
Proxy filing7 Apr 2026 - Diversified growth, major launches, and pipeline advances drive optimism for 2024 and beyond.MNKD
Leerink Global Healthcare Conference 202613 Mar 2026 - Double-digit growth and two major launches expected as diversification and innovation accelerate.MNKD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Strong revenue growth, advancing pipeline, and new launches drive optimistic outlook.MNKD
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Q1 revenue up 18% to $78.4M, net income up 24%, and pipeline advancing in key programs.MNKD
Q1 20253 Feb 2026 - Q2 revenue up 49% to $72.4M, pipeline advances, and liquidity strengthened by debt reduction.MNKD
Q2 20242 Feb 2026